Maze Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
MAZE$34.91+2.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance sheets
(in thousands, except share and per share data)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $196,812 | $29,158 |
| Prepaid expenses and other current assets | 4,859 | 4,952 |
| Total current assets | 201,671 | 34,110 |
| Property and equipment, net | 6,668 | 8,845 |
| Restricted cash | 1,088 | 1,088 |
| Operating lease right-of-use asset | 23,250 | 26,139 |
| Other assets | 7,865 | 1,322 |
| Total assets | $240,542 | $71,504 |
| Liabilities, Redeemable Convertible Preferred Stock and Stockholders’ Deficit | ||
| Current liabilities: | ||
| Accounts payable | $1,939 | $2,019 |
| Accrued expenses and other current liabilities | 14,102 | 9,808 |
| Operating lease liabilities, current | 4,632 | 4,489 |
| Total current liabilities | 20,673 | 16,316 |
| Operating lease liabilities, net of current portion | 21,996 | 25,054 |
| Convertible promissory notes | — | 20,080 |
| Other liabilities, non-current | 969 | — |
| Total liabilities | 43,638 | 61,450 |
| Commitments and contingencies (Note 8) | ||
| Redeemable convertible preferred stock, $0.001 par value; 298,205,027 and 203,415,024 shares authorized as of December 31, 2024 and 2023, respectively; 297,205,041 and 203,415,024 shares issued and outstanding as of December 31, 2024 and 2023, respectively; aggregate liquidation preference of $502,390 and $383,902 as of December 31, 2024 and 2023, respectively | 508,087 | 383,902 |
| Stockholders’ deficit: | ||
| Common stock, $0.001 par value; 410,000,000 and 261,000,000 shares authorized as of December 31, 2024 and 2023, respectively; 2,446,864 and 2,385,212 shares issued and outstanding as of December 31, 2024 and 2023, respectively; 10,372 and 62,629 shares subject to repurchase as of December 31, 2024 and 2023, respectively | 2 | 2 |
| Additional paid-in-capital | 47,242 | 21,836 |
| Accumulated deficit | (358,427) | (395,686) |
| Total stockholders’ deficit | (311,183) | (373,848) |
| Total liabilities, redeemable convertible preferred stock and stockholders’ deficit | $240,542 | $71,504 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.